Latest News & Updates
Breaking News
11 hours ago
Vaibhavi M.
Other trending news you may like to read
Zydus Launches Semaglutide Injection With Reusable Pen To Improve Diabetes Care Access, Patent Expiry Opens Door For Affordable GLP-1 Therapy
Zydus Lifesciences launches semaglutide injection under brands SEMAGLYN, MASHEMA, and ALTERME in India with a reusable multi-dose pen, priced at approximately ₹2,200 per month.
Vaibhavi M.
Glenmark Launches Affordable Semaglutide GLIPIQⓇ To Expand Diabetes Care Access In India, Sets New Cost Benchmark For GLP-1 Therapy With Flexible Dosing Options
Glenmark Pharmaceuticals launches GLIPIQ (semaglutide) in India for Type 2 diabetes after CDSCO approval, with weekly costs from ₹325 and a patient support program called Sankalp.
Vaibhavi M.
Bristol Myers Squibb’s Opdivo Gains Dual US And EU Approvals In Hodgkin Lymphoma, Opdivo Combinations Deliver Strong Survival Benefits
FDA and European Commission approve Bristol Myers Squibb's Opdivo (nivolumab) for classical Hodgkin lymphoma in separate combination regimens, backed by Phase III SWOG 1826 trial data.
Vaibhavi M.
20260321150630.png&w=640&q=75&dpl=dpl_2iKkC6jua4jraQoKLHmDXPkssQjV)
Macau Grants First Asian Approval To ImmunityBio’s ANKTIVA For Bladder Cancer, Expands Global Reach As ANKTIVA Wins Regulatory Clearance
Macau's ISAF approves ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln) combined with BCG for BCG-unresponsive NMIBC, marking ANKTIVA's first regulatory approval in Asia.
Vaibhavi M.
